\BOOKMARK [0][-]{chapter*.1}{ABSTRACT}{}% 1
\BOOKMARK [0][-]{chapter*.2}{DEDICATION}{}% 2
\BOOKMARK [0][-]{chapter*.3}{ACKNOWLEDGEMENTS}{}% 3
\BOOKMARK [0][-]{chapter*.4}{CONTRIBUTORS\040AND\040FUNDING\040SOURCES}{}% 4
\BOOKMARK [0][-]{chapter*.5}{NOMENCLATURE}{}% 5
\BOOKMARK [0][-]{section*.6}{TABLE\040OF\040CONTENTS}{}% 6
\BOOKMARK [0][-]{section*.7}{LIST\040OF\040FIGURES}{}% 7
\BOOKMARK [0][-]{section*.8}{LIST\040OF\040TABLES}{}% 8
\BOOKMARK [0][-]{chapter.1}{UBE3A\040imprinting\040in\040neurons:\040a\040unique\040model\040for\040antisense\040lncRNA\040regulation}{}% 9
\BOOKMARK [1][-]{section.1.1}{Diseases\040of\040Chromosome\04015q11-q13}{chapter.1}% 10
\BOOKMARK [2][-]{subsection.1.1.1}{Prader-Willi\040Syndrome}{section.1.1}% 11
\BOOKMARK [2][-]{subsection.1.1.2}{Chromosome\04015q11-q13\040Duplication\040Syndrome}{section.1.1}% 12
\BOOKMARK [2][-]{subsection.1.1.3}{Angelman\040Syndrome}{section.1.1}% 13
\BOOKMARK [1][-]{section.1.2}{Ubiquitin\040Ligase\040E3A\040Protein\040Gene}{chapter.1}% 14
\BOOKMARK [2][-]{subsection.1.2.1}{UBE3A\040in\040Neurons}{section.1.2}% 15
\BOOKMARK [1][-]{section.1.3}{Genomic\040Imprinting}{chapter.1}% 16
\BOOKMARK [2][-]{subsection.1.3.1}{Imprinting\040Control\040Regions}{section.1.3}% 17
\BOOKMARK [1][-]{section.1.4}{Function\040of\040Imprinting}{chapter.1}% 18
\BOOKMARK [2][-]{subsection.1.4.1}{Dosage\040Regulation}{section.1.4}% 19
\BOOKMARK [2][-]{subsection.1.4.2}{Regulatory\040Function}{section.1.4}% 20
\BOOKMARK [1][-]{section.1.5}{Long\040Non-Coding\040RNA}{chapter.1}% 21
\BOOKMARK [1][-]{section.1.6}{Antisense\040lncRNA}{chapter.1}% 22
\BOOKMARK [2][-]{subsection.1.6.1}{FGFR2-AS}{section.1.6}% 23
\BOOKMARK [2][-]{subsection.1.6.2}{Airn}{section.1.6}% 24
\BOOKMARK [2][-]{subsection.1.6.3}{Nespas}{section.1.6}% 25
\BOOKMARK [2][-]{subsection.1.6.4}{Nudt6}{section.1.6}% 26
\BOOKMARK [2][-]{subsection.1.6.5}{Kcnq1ot1}{section.1.6}% 27
\BOOKMARK [2][-]{subsection.1.6.6}{BACE1-AS}{section.1.6}% 28
\BOOKMARK [2][-]{subsection.1.6.7}{BDNF-AS}{section.1.6}% 29
\BOOKMARK [2][-]{subsection.1.6.8}{Ube3a-AS}{section.1.6}% 30
\BOOKMARK [1][-]{section.1.7}{Concluding\040Remarks}{chapter.1}% 31
\BOOKMARK [0][-]{chapter.2}{The\040Prader-Willi\040syndrome\040polycistronic\040transcriptional\040unit\040undergoes\040extensive\040processing\040and\040is\040spatiotemporally\040regulated\040in\040brain}{}% 32
\BOOKMARK [1][-]{section.2.1}{Introduction}{chapter.2}% 33
\BOOKMARK [1][-]{section.2.2}{Materials\040&\040Methods}{chapter.2}% 34
\BOOKMARK [2][-]{subsection.2.2.1}{Public\040data,\040genomes\040and\040annotations}{section.2.2}% 35
\BOOKMARK [2][-]{subsection.2.2.2}{Data\040processing}{section.2.2}% 36
\BOOKMARK [1][-]{section.2.3}{Results}{chapter.2}% 37
\BOOKMARK [2][-]{subsection.2.3.1}{The\040PWS-PTU\040is\040processed\040into\040smaller\040transcriptional\040units}{section.2.3}% 38
\BOOKMARK [2][-]{subsection.2.3.2}{Transcriptional\040regulation\040of\040the\040PWS-PTU\040is\040different\040between\040mouse\040and\040human}{section.2.3}% 39
\BOOKMARK [2][-]{subsection.2.3.3}{The\040PWS-PTU\040is\040differentially\040expressed\040among\040brain\040regions\040and\040during\040brain\040development}{section.2.3}% 40
\BOOKMARK [2][-]{subsection.2.3.4}{Polyadenylated\040Ube3a-AS\040is\040a\040relatively\040stable\040transcript\040that\040differentially\040localizes\040between\040the\040nucleus\040and\040cytoplasm}{section.2.3}% 41
\BOOKMARK [1][-]{section.2.4}{Discussion}{chapter.2}% 42
\BOOKMARK [0][-]{chapter.3}{Antisense\040mediated\040alternative\040splicing\040regulates\040imprinting\040of\040Ube3a\040in\040neurons}{}% 43
\BOOKMARK [1][-]{section.3.1}{Introduction}{chapter.3}% 44
\BOOKMARK [1][-]{section.3.2}{Materials\040&\040Methods}{chapter.3}% 45
\BOOKMARK [2][-]{subsection.3.2.1}{Animals}{section.3.2}% 46
\BOOKMARK [2][-]{subsection.3.2.2}{Primary\040neuronal\040culture}{section.3.2}% 47
\BOOKMARK [2][-]{subsection.3.2.3}{3'\040Rapid\040amplification\040of\040cDNA\040ends\040analysis}{section.3.2}% 48
\BOOKMARK [2][-]{subsection.3.2.4}{Cell\040culture\040treatment\040with\040Topotecan\040and\040ASO-B}{section.3.2}% 49
\BOOKMARK [2][-]{subsection.3.2.5}{Reverse-transcription\040and\040quantitative\040PCR\040analysis}{section.3.2}% 50
\BOOKMARK [2][-]{subsection.3.2.6}{RNA-sequencing\040analysis}{section.3.2}% 51
\BOOKMARK [1][-]{section.3.3}{Results}{chapter.3}% 52
\BOOKMARK [1][-]{section.3.4}{Discussion}{chapter.3}% 53
\BOOKMARK [0][-]{chapter.4}{High\040throughput\040drug\040screening\040of\040mouse\040embryonic\040stem\040cell-derived\040neurons}{}% 54
\BOOKMARK [1][-]{section.4.1}{Mouse\040Embryonic\040Stem\040Cell\040Culture\040\(Timing:\0405\040days\)}{chapter.4}% 55
\BOOKMARK [2][-]{subsection.4.1.1}{Plating\040feeder\040cells\040for\040co-culture}{section.4.1}% 56
\BOOKMARK [2][-]{subsection.4.1.2}{Plating\040ES\040cells}{section.4.1}% 57
\BOOKMARK [1][-]{section.4.2}{Neural\040Induction\040\(Timing:\0407\040days\)}{chapter.4}% 58
\BOOKMARK [1][-]{section.4.3}{Neuron\040Elongation\040&\040Maturation\040\(Timing:\0402+\040days\)}{chapter.4}% 59
\BOOKMARK [1][-]{section.4.4}{Representative\040Results}{chapter.4}% 60
\BOOKMARK [1][-]{section.4.5}{Discussion}{chapter.4}% 61
\BOOKMARK [1][-]{section.4.6}{Materials}{chapter.4}% 62
\BOOKMARK [0][-]{chapter.5}{Mouse\040embryonic\040stem\040cell-derived\040neuron\040high-throughput\040drug\040screen\040assay\040for\040Angelman\040syndrome}{}% 63
\BOOKMARK [1][-]{section.5.1}{Introduction}{chapter.5}% 64
\BOOKMARK [1][-]{section.5.2}{Materials\040and\040Methods}{chapter.5}% 65
\BOOKMARK [2][-]{subsection.5.2.1}{Animals}{section.5.2}% 66
\BOOKMARK [2][-]{subsection.5.2.2}{Generation\040of\040Ube3a+/YFP\040embryonic\040stem\040cells}{section.5.2}% 67
\BOOKMARK [2][-]{subsection.5.2.3}{Neuronal\040Differentiation}{section.5.2}% 68
\BOOKMARK [2][-]{subsection.5.2.4}{Immunocytochemistry}{section.5.2}% 69
\BOOKMARK [2][-]{subsection.5.2.5}{Image\040analysis}{section.5.2}% 70
\BOOKMARK [2][-]{subsection.5.2.6}{Charts}{section.5.2}% 71
\BOOKMARK [1][-]{section.5.3}{Results}{chapter.5}% 72
\BOOKMARK [2][-]{subsection.5.3.1}{Topotecan\040induces\040reactivation\040of\040silenced\040paternal\040Ube3a\040allele\040in\040ES\040cell-derived\040neurons}{section.5.3}% 73
\BOOKMARK [2][-]{subsection.5.3.2}{Plate\040effect\040is\040not\040observed\040for\040the\040NeuN-Overlap\040method}{section.5.3}% 74
\BOOKMARK [2][-]{subsection.5.3.3}{Well\040position\040effects\040Ube3aYFP\040intensity}{section.5.3}% 75
\BOOKMARK [1][-]{section.5.4}{Discussion}{chapter.5}% 76
\BOOKMARK [0][-]{chapter.6}{Conclusion}{}% 77
\BOOKMARK [1][-]{section.6.1}{Ube3a-AS\040demonstrates\040complex\040expression\040within\040the\040brain}{chapter.6}% 78
\BOOKMARK [1][-]{section.6.2}{Ube3a\040paternal\040isoform\0404\040supports\040additional\040regulatory\040functions\040of\040Ube3a-AS}{chapter.6}% 79
\BOOKMARK [1][-]{section.6.3}{Embryonic\040stem\040cells\040are\040a\040versatile\040source\040for\040high-throughput\040screening}{chapter.6}% 80
\BOOKMARK [1][-]{section.6.4}{Future\040studies}{chapter.6}% 81
\BOOKMARK [2][-]{subsection.6.4.1}{Further\040characterization\040of\040Ube3a\040isoform\0404\040and\040Ube3a-AS}{section.6.4}% 82
\BOOKMARK [2][-]{subsection.6.4.2}{Exon\040skipping\040of\040Ube3a\040isoform\0404\040as\040a\040therapeutic\040strategy\040for\040Angelman\040syndrome}{section.6.4}% 83
\BOOKMARK [2][-]{subsection.6.4.3}{High-throughput\040screening\040assays}{section.6.4}% 84
\BOOKMARK [0][-]{section*.34}{REFERENCES}{}% 85
\BOOKMARK [0][-]{APPENDIX.a.A}{APPENDIX\040Known\040UBE3A\040protein\040interactions}{}% 86
\BOOKMARK [0][-]{APPENDIX.a.B}{APPENDIX\040Supplemental\040Data\040-\040Chapter\040Two}{}% 87
\BOOKMARK [0][-]{APPENDIX.a.C}{APPENDIX\040Supplemental\040Data\040-\040Chapter\040Three}{}% 88
\BOOKMARK [0][-]{APPENDIX.a.D}{APPENDIX\040Supplemental\040Data\040-\040Chapter\040Five}{}% 89
\BOOKMARK [0][-]{APPENDIX.a.E}{APPENDIX\040Protocols}{}% 90
\BOOKMARK [1][-]{section.a.E.1}{Genotyping}{APPENDIX.a.E}% 91
\BOOKMARK [2][-]{subsection.a.E.1.1}{DNA\040extraction}{section.a.E.1}% 92
\BOOKMARK [2][-]{subsection.a.E.1.2}{Ube3aYFP\040Genotyping}{section.a.E.1}% 93
\BOOKMARK [2][-]{subsection.a.E.1.3}{Gel\040Electrophoresis}{section.a.E.1}% 94
\BOOKMARK [1][-]{section.a.E.2}{High-throughput\040Image\040Analysis}{APPENDIX.a.E}% 95
\BOOKMARK [2][-]{subsection.a.E.2.1}{Image\040Processing}{section.a.E.2}% 96
\BOOKMARK [2][-]{subsection.a.E.2.2}{R\040programming\040analysis}{section.a.E.2}% 97
\BOOKMARK [1][-]{section.a.E.3}{Immunocytochemistry}{APPENDIX.a.E}% 98
\BOOKMARK [2][-]{subsection.a.E.3.1}{Fixation\040-\040Cell\040Culture}{section.a.E.3}% 99
\BOOKMARK [2][-]{subsection.a.E.3.2}{Staining\040-\040Cell\040Culture}{section.a.E.3}% 100
\BOOKMARK [1][-]{section.a.E.4}{Rapid\040Amplification\040of\040cDNA\040Ends\040\(3'\)}{APPENDIX.a.E}% 101
\BOOKMARK [2][-]{subsection.a.E.4.1}{First-Strand\040cDNA\040Synthesis}{section.a.E.4}% 102
\BOOKMARK [2][-]{subsection.a.E.4.2}{Amplification\040of\040Target\040cDNA}{section.a.E.4}% 103
\BOOKMARK [2][-]{subsection.a.E.4.3}{Electroporation\040Cloning\040&\040Insert\040Verification}{section.a.E.4}% 104
\BOOKMARK [1][-]{section.a.E.5}{Reverse-transcription\040PCR/qPCR}{APPENDIX.a.E}% 105
\BOOKMARK [2][-]{subsection.a.E.5.1}{First-Strand\040Synthesis}{section.a.E.5}% 106
\BOOKMARK [2][-]{subsection.a.E.5.2}{SYBR\040Green\040qPCR}{section.a.E.5}% 107
\BOOKMARK [1][-]{section.a.E.6}{RNA\040Extraction}{APPENDIX.a.E}% 108
\BOOKMARK [2][-]{subsection.a.E.6.1}{Tissue\040RNA\040isolation}{section.a.E.6}% 109
\BOOKMARK [2][-]{subsection.a.E.6.2}{Cell\040culture\040RNA\040isolation}{section.a.E.6}% 110
\BOOKMARK [2][-]{subsection.a.E.6.3}{Cytoplasm\040&\040nuclear\040cell\040RNA\040isolation}{section.a.E.6}% 111
